Фенотипическое исследование активности изоферментов цитохрома Р450 у больных шизофренией с использованием кофеина в качестве тест-субстрата
Диссертация
Разработанная методология позволяет повысить безопасность антипсихотической терапии, обосновывая необходимость дифференцированного подхода к назначению и правильному дозированию субстратов изофермента цитохрома Р450 1А2 на основе оценки окислительной способности печени по отдельным изоферментам. Результаты исследования внедрены в практику Республиканской клинической психиатрической больницы… Читать ещё >
Список литературы
- Арчаков АИ. Цитохромы Р-450, лекарственная болезнь и персонифицированная медицина. Часть I. / Арчаков АИ, Лисица АВ, Петушкова НА, Карузина ИИ. // Клиническая медицина. 2008. — № 2. — С.4−8.
- Балткайс ЯЯ, Фатеев ВА. Взаимодействие лекарственных веществ (фармакотерапевтические аспекты). М.: Медицина. 1991.
- Белоусов ЮБ, Моисеев ВС, Лепахин ВК. Клиническая фармакология и фармакотерапия, Москва. -2000. стр.478−485.
- Белоусов ЮБ. Основы клинической фармакологии и рациональной фармакотерапии. / Под общ. ред. Ю. Б. Белоусова, М. В. Леоновой. — М.: Бионика, 2002. — 368 с. —¦ (Рациональная фармакотерапия: Сер. рук. Для практикующих врачей: Т.1).
- Вартанян ФЕ. Взаимосвязь генетических и средовых факторов с фармакотерапией // Клиническая фармакология и терапия. 2006. — Т. 15, № 2.-С.86,88.
- Ведерникова ОО. Фенотипический анализ эффективности биотрансформации лекарств и возможности ее фармакологической коррекции. Автореф. диссер. на соиск. уч. степени канд. мед. наук. 2005.
- Габина СВ. Возрастные особенности активности цитохрома Р, 450 и его изоферментов у здоровых детей. // Габина СВ, Переслегина ИА, Коркоташвили ЛВ. // Клиническая лабораторная диагностика. 2005. — № 1. — С.20,22.
- Гилман АГ. Клиническая фармакология по Гудману и Гилману. Редакторы Дж. Хардман и Л. Лимберд. В четырех томах. Пер. с англ. М., Практика, 2006. — 520 с.
- Денисов ИН, Шевченко ЮЛ. Клинические рекомендации -фармакологический справочник / М.: ГЭОТАР-МЕД, 2004. -1184 с. — (Серия «Доказательная медицина»).
- Деримедведь ЛВ. Взаимодействие лекарств и эффективностьфармакотерапии. /, И. М. Перцев, Е. В. Шуванова, И. А. Зупаиец, В.Н. Хоменко- под ред. И. М. Перцева.- X.: Изд-во «Мегаполис», 2001.
- Дутов АА. О принципах и проблемах терапевтического мониторинга лекарств // Лаборатория. 2004. — № 4. — С.2,4.
- Дутов АА. Хроматография в практической медицине (Обзор II) // Забайкальский медицинский вестник. 2002. — № 2. — С.27,34.
- Збровский АБ. Осложнения фармакотерапии. Збровский АБ, Тюренков ИН. М.: Медицина, 2003. — 544 с.
- Золотов ЮА. Основы аналитической химии-в 2 кн. Кн.1. Общие вопросы. Методы разделения: Учеб. для вузов/ Золотов Ю. А., Дорохова Е. Н., Фадеева В. И. и др.- М.: Высш.шк., 1996. стр. 298−373
- Каркищенко НН. Фармакокинетика. / Н. Н. Каркищенко, В. В. Хоронько, С. А. Сергеева, В. Н. Каркищенко. Ростов н/Д: Феникс, 2001. -384 с.
- Катцунг Г. Бертрам. Базисная и клиническая фармакология. -СПб. -Невский Диалект. -1998. Т.1. С. 73−86.
- Кукес ВГ, Стародубцев АК. Клиническая фармакология и фармакотерапия. М.:ГЕО-ТАР-МЕД, 2003.
- Кукес ВГ, Сычев ДА. Особенности клинической фармакологии у беременных, кормящих матерей, новорожденных и пожилых. Клиническая фармакология под ред. Академика РАМН, проф Кукеса В. Г. М. ТЕОТАР-МЕД, 2004.
- Кукес ВГ, Фисенко ВП, Стародубцев АК, Раменская ГВ, Сычев ДА, Андреев ДА, Рейхарт ДВ. Метаболизм лекарственных препаратов под ред. Академика РМН, проф Кукеса В. Г., чл.-коор. РАМН, проф. Фисенко В. П. М.: Палея-М, 2001.
- Кукес ВГ. Метаболизм лекарственных средств: клинико-фармакологические аспекты. -М.: Издательство «Реафарм», 2004.
- Кукес ВГ. Клиническая фармакология: Учебник. / 3-е издание, переработанное и дополненное. — М.: ГЭОТАР-МЕД, 2004. — 944 е.: ил.
- Куценко СА. Основы токсикологии. СПб.: Фолиант, 2004. — 720
- Лоуренс ДР, Беннит ПН. Клиническая фармакология. М.-Медицина.-1993. Т.1. С. 208−215.
- Лакин КМ, Крылов ЮФ. Биотрансформация лекарственных веществ.- М.: Медицина, 1981.-344 с.25- Лильин ЕТ, Богомазов ЕА, Гофман-Кадошников ПБ. Генетика для врача. М.: Медицина, 1990.-е. 176−187
- Маевская MB. Алкогольная болезнь печени // Consilium medicum. 2001. — Т. 3, № 6. — С.256,260.
- Мирошниченко ИИ. Генетический полиморфизм и фармакокинетика лекарственных средств. / Мирошниченко ИИ, Птицина СН. // Клиническая фармакокинетика. 2005. — Т. 3, № 2. — С.35,39.
- Петров РВ, Зиганшина ЛЕ. Лекарственные средства (Справочник-путеводитель практикующего врача) / М., 2003 800 с. (Серия «Доказательная медицина»)
- Пирузян АЛ. Фармакогепомика: путь к индивидуализированной терапии. / Пирузян АЛ. // Экспериментальная и клиническая фармакология. -2005.-Т. 68, № 5. С. 59,67.
- Пирузя?! ЛА. Прогностический фактор риска развития патологических процессов, основанный на полиморфизме ферментов метаболизма ксенобиотиков. / Пирузян ЛА, Суханов ВА, Саприн ВА. // Физиология человека. 2000. — Т. 26, № 2. — С. 115,123.
- Пруткина ЕВ. Роль особенностей метаболического статуса в формировании резистентности организма и патологии. / Пруткина ЕВ, Цыбиков НН. // Сибирский медицинский журнал. 2007. — № 5.
- Раменская ГВ. Высокоэффективная жидкостная хроматография в оценке биотрансформации лекарственных средств (фармакокинетика и фармакогенетика). Автореф. диссер. на соиск. уч. степени докт. фарм. наук. 2003.
- Сергиенко ВИ. Математическая статистика в клинических исследованиях. / В. И. Сергиенко, И. Б. Бондарева. — М.: ГЭОТАР-МЕД, 2001. — 56с.
- Середеиин СБ. Лекции по фармакогенетике. М.: Медицинское информационное агентство, 2004. — 303 с.
- Соколов АВ. Терапевтический лекарственный мониторинг. / Соколов АВ. // Качественная клиническая практика. — 2002. № 1. — С.35,40.
- Степанов ЮМ. Лекарственные поражения печени: патогенез, классификация, диагностика, лечение. / Степанов ЮМ, Филиппова АЮ, Кононов ИН. // Мистецво лкування. -2005. -№ 3. С. 10,12.
- Сычев ДА, Раменская ГВ, Игнатьев ИВ, Кукес ВГ. Клиническая фармакогенетика, ВГ Кукес, НП Бочкова (ред.) М.: ГЭОТАР-Медиа — 2007.
- Сычев ДА. Клиническая фармакогенетика. Клиническая фармакокинетика. Клиническая фармакология под ред. Академика РАМН, проф Кукеса В. Г. М.:ГЕОТАР-МЕД, 2004.
- Сычев ДА. Половые различия в биотрансформации лекарственных средств: значение для проведения клинических исследований лекарственных средств. // Сычев ДА, Раменская ГВ, Кукес ВГ. // Клиническая фармакокинетика. -2005. Т. 2, № 1. — С. 15,17.
- Хабриев РУ. Лекарственные средства (справочное издание). / Хабриев РУ. Чучалин АГ, Зиганшина ЛЕ. // М.: «ГЭОТАР-МЕДИА», 2005. — 563 с.
- Хайс РХ. Биологические эффекты токсических соединений: курс лекций // Хайс РХ, Гуляева ЛФ. // Новосиб. гос. ун-т. Новосибирск, 2003. 208 с.
- Холодов ЛЕ. Клиническая фармакокинетика. / Холодов ЛЕ, Яковлев ВП. М.: Медицина, 1985. — 464 с.
- Хроматография. Продукты для анализа и очистки. SUPELCO. 2003−2004
- Abdelmawla N. Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms. / Abdelmawla N, Mitchel AJ. // Adv Psych Treatm. -2006.-V.12. pp. 35−44.
- Alkaysi HN. High performance liquid chromatographic analysis of caffeine concentrations in plasma and saliva. / Alkaysi HN, Salem MS et al. // J Clin Pharmacy Ther. — 1988. V.13.—pp. 109—115.
- Allorge D. Identification of a novel splice-site mutation in the CYP1A2 gene. / Allorge D, Chevalier D, Lo-Guidice JM et al. // Br J Clin Pharmacol. 2003. — V.56. — pp. 341−344.
- Alvir JMJ. Clozapine-induced agranulocytosis. / Alvir JMJ, Lieberman JA, Safferman AZ ct al. // N Engl J Med. 1993. — V.329. — pp. 162 167.
- Anderson GD. A mechanistic approach to antiepileptic drug interactions. / Anderson GD et al. // Ann Pharmacother. 1998. — V.32. — pp. 554 563.
- АТС classification index with DDDs, January 2006, WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway
- Avenoso A. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia. / Avenoso A, Facciola G et al. // Clin Drug Invest. 1998. — V.16. — pp. 393−398.
- Bachman KA. Genotyping and phenotyping the cytochrome P-450 enzymes. / Bachman KA. // Am J Ther. 2002. — № 9. — pp.309−316.
- Baird P. Beware of cytochrome P450 inducers. / Baird P et al. // Curr Psychiatry. 2002. V. 1. — pp. 11−16.
- Barnas C. Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. / Barnas C,
- Zwierzina H, Hummer M et al. // J Clin Psychiatry. 1992. V.53. — pp. 245−247.
- Bazire S. Psychotropic Drug Directory: The professionals' pocket handbook & aid memoire. 2005.
- Beasley CM Jr. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. / Beasley CM Jr, Hamilton SH, Crawford AM et al. // Eur Neuropsychopharmacol. — 1997. — V.7. — pp. 125— 137.
- Beasley CM. Safety of olanzapine. / Beasley CM et al. // J Clin Psychiatry Monograph. 1997. — V.15(2). — pp. 19−21.
- Bebia Z. Вioequivalence revisted: Influence of age and sex on CYP enzymes. / Bebia Z et al. // Clin Pharmacol Ther. 2004. — V.76(6). — pp. 618−627.
- Bertilsson L. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. / Bertilsson L, Carrillo JA et al. // Br J Clin Pharmacol. 1994. — V.38(5). — pp. 471−473.
- Blanchard J. Improved Liquid-Chromatographic Determinationof Caffeine in Plasma. / Blanchard J, Mohammadi JD et al. // Clin Chem. 1980. -V.26/9. — pp. 1351−1354.
- Bock ICW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics. 1994−4:209−218. PubMed.
- Bonati M. Caffeine disposition after oral doses. / Bonati M, Latini R et al. // Clin Pharmacol Ther. 1982. — V.32(l). — pp. 98−106.
- British National Formulary. 2008.
- Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. / Brosen К et al. // Therapie. 2004. — V.59. pp. 5−12.
- Buchanan RW. The schizophrenia PORT pharmacological treatment recommendations: conformance and Implications for symptoms and functionaloutcome. / Buchanan RW, Kreyenbuhl J, Zito JM et al. // Schizophrenia Bulletin. -2002.-V.28.-pp. 63−73.
- Butler MA. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. / Butler MA, Lang NP, Young JF et al. // Pharmacogenetics. 1992. — V.2. — pp. 116−127.
- Caligiuri MP. Incidence and risk factors for severe tardive dyskinesia in older patients. / Caligiuri MP, Lacro J P, Rockwell E. // British Journal of Psychiatry. — 1997.—V.171.—pp. 148−153.
- Callaghan JT. Olanzapine, pharmacokinetic and pharmacodynamic profile. / Callaghan JT, Bergslrom RF et al. // Clin Pharmacokinet. 1999. — V.37. -pp. 177−193.
- Campbell ME. A urinary metabolite ratio that reflects systemic caffeine clearance. / Campbell ME, Spielberg SP, Kalow W. // Clin Pharmacol Ther. 1987. -V.42. -pp. 157−165.
- Caraco Y. Caffeine pharmacokinetics in obesity and following significant weight reduction. / Caraco Y, Zylber-Katz E et al. // Int J Obes Relat Metab Disord. 1995. — V. 19(4). — pp. 234−239.
- Caroff S. The neuroleptic malignant syndrome. / Caroff S et al. // J Clin Psychiatry. 1980. — V.41. — pp. 79−83.
- Carregaro AB. Comparison of the quantification of caffeine in human plasma by gas chromatography and ELISA. / Carregaro AB, Woods WE, Tobin ТА. // Braz J Med Biol Res. -2001, — V.34. pp. 821 -824.
- Carrillo J. Evaluation of Caffeine as an In Vivo Probe for CYP1A2 Using Measurements in Plasma, Saliva, and Urine. / Carrillo J, Christensen M et al. // Ther Drug Monit. 2000. — V.22(4). — pp. 409−417.
- Carrillo JA. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. / Carrillo JA, Benitez J. // Clin Pharmacol Ther. 1994. — V.55. — pp. 293−304.
- Carrillo JA. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Carrillo JA, Herraiz AG et al. // J Clin Psychopharmacol. 2003. — V.23. — pp. 119−127.
- Catteau A, Bechtel YC, Poisson N, Bechtel PR. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol. 1995−47:423−430.
- Chakos MH. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. / Chakos MH, Alvir JM, Woerner MG. // Arch Gen Psychiatry. — 1996. — V.53. — pp. 313−319.
- Chang GW. The physiological and" pharmacological roles of cytochrome P450 isoenzymes. / Chang GW, Kam PCA. // Anaesthesia. 1999. -V.54. — p- 42.
- Chetty M. CYP-mediated clozapine interactions: how predictable are they? / Chetty M, Murray M. // Curr Drug Metab. 2007. — V.8(4). — pp. 307−313.
- Christensen LM. Daily 10-mg and 20mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P450 1A2) and omeprazole (cytochrome P450 2C19). / Christensen LM et al. // Clin Pharmacol Ther. 2003. -V.74(2). — p. 144.
- Cohen S. Weight gain associated with clozapine. / Cohen S, Chiles J, MacNaughton A. // Am J Psychiatry. 1990. — V.147. pp. 503−504.
- Culter A. Dosing atypical antipsychotics. / Culter A. // CNS Spectr. -2008.-V.13(9).-pp. 3−14.
- Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics, useful aid to prescribing. / Dahl ML et al. // Clin Pharmacokinet. 2002. — V.41. — pp. 453−470.
- Dahl SG. Pharmacokinetics of antipsychotic drugs in man. / Dahl SG. //Acta Psychiatr Scand Suppl. — 1990. — V.358. — pp. 37−40.
- Daniel WA. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes. / Daniel WA, Syrek M et al. // Pol J Pharmacol. 2001. — V.53. — pp. 351−357.
- Daniel WA. Effects Of Classic And Newer Antidepressants On The Oxydation Pathways Of Caffeine In Rat Liver In Vitro Study. / Daniel WA, Kot M, Wojcikowski J. // Pol J Pharmacol. 2003. — V.55. — pp. 1045−1053.
- Denaro CP. The effect of liver disease on urine caffeine metabolite ratios. / Denaro CP, Wilson M. // Clin. Pharmacol. Ther. 1996. — V.59(6). — pp. 624−635.
- Diaz FJ. Plasma clozapine concentration coefficients of variation in a long-term study. / Diaz FJ, de Leon J et al. // Schizophr Res. 2005. — V.72. — pp. 131−135.
- Donato MT. Fluorescence-Based Assays For Screening Nine Cytochrome P450 Activities In Intact Cells Expressing Individual Human P450
- Enzymes. / Donato MT, Jimenez N et al. Drug Metab Dispos. 2004. — V.32. -pp. 699−706.
- Donovan JL. A Primer on Caffeine Pharmacology and Its Drug Interactions in Clinical Psychopharmacology. / Donovan JL. // Psychopharmacol bulletin.-2001. —V.35(3).
- Doude van Troostwijk LJ. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. / Doude van Troostwijk LJ, Koopmans RP. // Eur J Pharm Sci. 2003. — V.20(4−5). — pp. 451−457.
- Enger C. Serious cardiovascular events and mortality among patients with schizophrenia. / Enger C, Weatherby L et al. // AM J Nerv Ment Dis. 2004. -Jan. 192(1).-pp. 19−27.
- Faber MS. Assessment of CYP1A2 activity in clinical practice: why, how, and when? / Faber MS, Jetter A, Fuhr U. / Basic Clin Pharmacol Toxicol. 2005. V.97(3). — pp. 125−134.
- Faber MS. Time response of cytocrome P450 1A2 activity on cessation of heavy smoking. / Faber MS et al. // Clin Pharmacol Ther. 2004. -V.76(2).-pp. 178−184.
- Fertig MK. Hyperglycemia associated with olanzapine letter. / Fertig MK, Brooks VG, Shelton PS et al. // J Clin Psychiatry. 1998. — V.59. — pp. 687 689.
- Fitzgerald B. Elevation of carbamazepine-10, 11-epoxide by quetiapine. / Fitzgerald B, Okos A. // Pharmacotherapy. 2002. — V.22. — pp. 1500−1503.
- Fontana RJ. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer’s disease. / Fontana RJ, deVries TM. // Br J Clin Pharmacol. 1998. — V.46(3). — pp. 221−228.
- Forsyth JT. Parkinson’s disease and CYP1A2 activity. / Forsyth JT, Grunewald RA et al. // Br J Clin Pharmacol. 2000. — V.50(4). — pp. 303−309.
- Frankenburg FR. Clozapine and body mass change. / Frankenburg FR, Zanarini MC, Kando J, Centorrino F // Biol Psychiatry 1998. — V.43. — pp. 520 524.
- Frye RF. Probing the World of Cytochrome P450 Enzymes. / Frye RF. // Molecular Interventions. 2004. — V.4. — pp. 157−162.
- Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994−4:109−116. PubMed.
- Fuhr U. Evaluation of caffeine as a test drug for CYP1A2, NAT2, CYP2E1 phenotyping in man by in vivo versus in vitro correlations. / Fuhr U, Rost KL, Engelhardt R et al. // Pharmacogenetics. 1996. — V.6. — pp. 159−76.
- Gatta B. Diabetic ketoacidosis with olanzapine treatment letter. / Gatta B, Rigalleau V, Gin H. // Diabetes Care. 1999. — V.22. — pp. 1002−1003.
- Gaulin BD. Clozapine-associated elevation in serum triglycerides. / Gaulin BD, Markowitz JS, Caley CF et al. // Am J Psychiatry. — 1999. — V.156. — pp. 1270−1272. Gatta B, Rigalleau V, Gin H.
- Geddes J. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. / Geddes J, Freemantle N, Harrison P et al. // BMJ. 2000. — V.231. — pp. 1371−1376.
- Gelly F. Long-term clinical experience with clozapine. / Gelly F, Chambon O, Marie-Cardine M. // Encephale. 1997. — V.23(5). — pp. 385−396.
- Gilar M. Determination of caffeine using high-performance liquid chromatography. / Gilar M, Perlik F, Patzelova V. // Ceska Slov Farm. 1994. — V.43(2). — pp. 78−80.
- Goldstein LE. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. / Goldstein LE, Spom J, Brown S et al. // Psychosomatics. 1999. — V.40. — pp. 438143.
- Grant D. Variability in caffeine metabolism. / Grant D, Tang B. // Clin Pharmacol Ther. 1983. — V.33. — pp. 591−602.
- Greenblatt DJ. Drug interactions with newer antidepressants: Role of human cytochromes P450. / Greenblatt DJ, von Moltlce LL et al. // J Clin Psychiatry. 1998. — V.59(l 5). — pp. 19−27.
- Haddad PM. Neurological complications of psychiatric drugs: clinical features and management. / Haddad PM, Dursun SM. // Hum Psychopharmacol. -2008. V.23(l). — pp. 15−26.
- Hamner MB. Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. / Hamner MB, Arana GW. // CNS Drugs. — 1998. —V. 10.—pp. 209−222.
- Harrison CM. Prescriptions for antipsychotics in general practice. / Harrison CM, Britt HC. // Med J Aust. -2003. V. 178(9). — pp. 468−469.
- Haughey DB. Liquid chromatographic determination of caffeine in biologic fluids. / Haughey DB. // J Chromatogr. — 1982. V.229. — pp. 387— 395.
- ITickman D. Evaluation of the Selectivity of In Vitro Probes and Suitability of Organic Solvents for the Measurement of Human Cytochrome P450 Monooxygenase Activities. / Hickman D, Wang JP et al. // J Drug Metab Dispos. -1998.- V.26.-pp. 207−215.
- Honigfeld G. The Clozapine National Registry System: forty years of risk management. / Honigfeld G. // J Clin Psychiatry Monograph. 1996. -V. 14(2).-pp. 29−32.127. http://www.cypalleles.ki.se/cyp 1 a2. htm
- Hunt CM. Effect of age and gender on the activity of human hepatic CYP3A. / Hunt CM, Westerkam WR, Stave GM. // Biochem Pharmacol. 1992. -V.44. — pp. 275−83.
- Ilett ICF, Castleden WM, Vandongen YK, Stacey MC, Butler MA, Kadlubar FF. Acetylation phenotype and cytochrome P450 1A2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther. 1993−54:317−322. PubMed.
- Ingelmann-Sundberg M. Human drug metabolizing cytochrome P450 enzymes: properties and polymorphism. / Ingelmann-Sundberg M. // Naunyn-Schmiedeberg's Arch Pharmacol. 2004. — V.369. — pp. 89−104.
- Ingelman-Sundberg M. REVIEW Human drug metabolising cytochrome P450 enzymes .'properties and polymorphisms. / Ingelman-Sundberg M. // Naunyn-Schmiedeberg's. Arch Pharmacol. — 2004. — V.369. — p. 89−104.
- Jeppsen U. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. / Jeppsen U, Gram LF et al. // Eur J Clin Pharmacol. 1996. — V.51. — pp. 73−78.
- Jodynis-Liebert J. Serum metabolite/caffeine ratios as a test for liver function. / Jodynis-Liebert J, Flieger J et al. // J Clin Pharmacol. 2004. — V.44(4). -pp.33 8−347.
- Joeres R. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology. / Joeres R, Brachtel DZ. // Gastroenterol. 1993. — V.31(2). -pp. 56−61.
- Joeres R. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. / Joeres R, Klinker H et al. // Hepatology. 1988. — V.8(3). — pp. 575−579.
- Jokinen MJ. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. // Jokinen MJ et al. // Clin Pharmacol Ther. -2001.-V.70. pp. -344−350.
- Jones PB. Randomized controlled trial of effect on quality of life of second-generation versus first generation antipsychotic drugs in schizophrenia. / Jones PB, Davies L, Barnes TR et al. // Arch Gen Psychiatry. 2006. — V.63. — pp. 1079−1087.
- Kadlubar F. Letter to the Editor. Correspondence re: Letter to the Editor by В. K. Tang and W. Kalow on CYP1A2 Phenotyping Using Caffeine. / Kadlubar F. // DrugMetab Rev. 1994. — V.26. — pp. 37−46.
- Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991−50:508−519.
- Kalow W. The use of caffeine for enzyme assays: a critical appraisal. / Kalow W, Tang BK. // Clin Pharmacol Ther. 1993. — V.53. — pp. 503−514.
- Kane JM. Adverse Effects of Psychotropic Drugs. / Kane JM, Lieberman JA. —New York: Guilford, 1992. — p. 536.
- Kapur S. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. / Kapur S, Remington G. // Annu Rev Med. -2001.-V.52.-pp. 503−517.
- Kroon L. Drug interactions with smoking. / Kroon L. // Am J Health Syst Pharm. 2007. — V.64(18). — pp. 1917−1921.
- Kusumoto M. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. / Kusumoto M, Ueno K, Oda A, et al. // Clin Pharmacol Ther. 2001. — V.69. — pp. 104−107.
- Lacy CF. Drug Information Handbook Pocket. 2004−2005. / Lacy CF, Goldman MP, Lance LL. // Hudson, OH, Lexi-Comp Inc. 2004.
- Leadbetter R. Clozapine-induced constipation letter. / Leadbetter R, Shutty M, Pavalonis D, et al. // Am J Psychiatry. 1992. — V.149. — pp. 68−72.
- Lehman AF. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. / Lehman AF, Steinwachs DM. // Schizophrenia Bulletin. 1998. — V.24. — pp. 1−10.
- Leo RJ. Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. / Leo RJ, Regno PD. J // Clin Psychiatry. 2000. — V.2(6). — pp. 194−204.
- Leo RJ. Cardiomyopathy associated with clozapine. / Leo RJ, Kreeger JL, Kim ICY. // Ann Pharmacother. 1996. — V. 30. — pp. 603−605.
- Leon J. The Dosing of Atypical Antipsychotics. / Leon J, Armstrong SC. // Psychosomatics. 2005. — V.46(6). — pp. 262−273.
- Levy RH. Metabolic Drug Interactions Philadelphia. / Levy RH, Thummmel KE et al. // Lippincott Williams & Wilkins. 2000.
- Liberman RP. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. / Liberman RP, van Putten T, Marshall BD Jr et al.//Am J Psychiatry. — 1994. — 151,—pp. 756−759.
- Lieberman JA. Clinical profile of clozapine: adverse reactions and agranulocytosis. / Lieberman J A, Safferman AZ. // Psychiatr Q. 1992. — V.63. -pp. 51−70.
- Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. / Lieberman JA, Stroup TS et al. // N Engl J Med. 2005. -V.353(12). — pp. 1286−1288.
- Lieberman JA. Maximizing clozapine therapy: managing side effects. / Lieberman JA. // J Clin Psychiatry. 1998. — V.59(3). — pp. 38−43.
- Linnet К. Metabolism of Clozapine by cDNA-Expressed Human Cytochrome P450 Enzymes. / Linnet K, Olesen OV. // Drug Metab Dispos. -1997.-V.25.-pp. 1379−1382.
- Lohr JB. Treatment predictors of extrapyramidal side effects in patients. / Lohr JB, Calligiuri MP, Edson R. // J Clin Psychopharmacol. 2002. -V. 22(2). Apr. — pp. 196−200.
- Maish WA. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. / Maish WA, Hampton EM et al. // Pharmacother. 1996. -V. 16(6).-pp. 1046−1052.
- Marinkovic D. The side effects of clozapine: a four year follow-up study. / Marinkovic D, Timotijevic I, Babinski T et al. // Prog Neuropsychopharmacol Biol Psychiatry. 1994. — V.18. — pp. 537−544.
- Martin K. Patterns of risperidone prescription: a utilization study in south-west France. / Martin K, Begaud В et al. // Acta Psychiatr Scand. 2004. -V. 109.-pp. 202−206.
- Masimirembwa CM. Heterologous Expression and Kinetic Characterization of Human Cytochromes P-450: Validation of a Pharmaceutical Tool for Drug Metabolism Research. / Masimirembwa CM, Otter С et al. // Drug Metab Dispos. 1999. — V.27. — pp. 1117−1122.
- Matzke GR. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. / Matzke GR et al. // Pharmacother. 2000. — V.20(2). — pp. 182−190.
- Mauri MC. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. / Mauri MC, Volonteri LS et al. // Clin Pharmacokinet. 2007. — V.46(5).-pp. 359−388.
- McEvoy J. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. / McEvoy J, Haughty G, Steingard S. // Arch Gen Psych. 1991. — V.48. — pp. 739−745.
- Metzger E. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. / Metzger E, Friedman R. // J Clin Psychopharmacol. 1993. — V.13(2). — pp. 128 132.
- Miller DD. Review and management of clozapine side effects. / Miller DD. // J Clin Psychiatry. 2000. — V.61(8). — pp. 14−17.
- Morgan M. Olanzapine overdose: a series of analytically confirmed cases. / Morgan M, Hackett LP, Isbister GK. // Int Clin Psychopharmacol. 2007. — V.22(3).-pp. 183−186.
- Naber D. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients. / Naber D, Leppig M. // Psychopharmacology (Bed). 1989. — V.99. — pp. 873−876.
- Odom-White A. Clozapine levels and caffeine. / Odom-White A, de Leon J. // J Clin Psychiatry. 1996. — V.57(4). — pp. 175−176.
- O’Malley K. Increased antipyrine half-life in women taking oral contraceptives. / O’Malley K, Stevenson IH, Alexander W. // Scott Med J. — 1970. — V. l 5 (12). — Dec. —pp. 454−456.
- Orlando R. Cytochrome P450 1A2 is a Major Determinant of Lidocaine Metabolism in Vivo: Effects of Liver Function. Orlando R. // Clin Pharmacol Ther. -2004. — V.75(l). pp. 80−88.
- Owen RR. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. / Owen RR, Thrush CR, Kirchner JE et al. // International Journal for Quality in Health Care. 2000. — V.12. — pp. 475−482.
- Ozdemir V. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. / Ozdemir V, Kalow W. // J Clin Psychopharmacol. 2001. -V.21(4). — pp. 398 407.
- Parker AC. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. / Parker AC, Pritchard P. // Br J Clin Pharmacol. 1998. — 45(2). — pp. 176−178.
- Parkinson A. Biotransformation of xenobiotics. In, Cassarett & Doulfs Toxicology: The Basic Science of Poisons, 5th ed. New York, McGraw-Hill. 1996.
- Patki КС. Effect of age on in vitro triazolam biotransformation in male human liver microsomes. / Patki КС, von Moltke LL, Harmatz JS et al. // Journal of Pharmacology And Experimental Therapeutics. — 2004. — V.308. — pp. 874 879.
- Perkins DO. Prolactin and endocrine related disorders. // Medical Illness in Schizophrenia. / Edited by Meyer JM, Nasrallah ITA. Arlington VA. — American Psychiatric Publishing. 2003. — pp. 215−232.
- Perlik F. Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis. / Perh’k F, Pucelfkova T, Slanar O. // Cas Lek Cesk. -2001.-V. 140(2).-pp. 51−53.
- Perry PJ. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. / Perry PJ, Bever KA, Arndt S, Combs MD. // Biol Psychiatry. 1998. — V.44. — pp. 733−738.
- Pirmohamed M. Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development. / Pirmohamed M, ParkK.//CNS Drugs. 1997.-V.7.-pp. 139−158.
- Pollack MIT. Genitourinary and sexual adverse effects of psychotropic medication. / Pollack MH, Reiter S, Hammerness P. // Int J Psychiatry Med. — 1992. —V.22.—pp. 305−327.
- Povlsen UJ. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. / Povlsen UJ, Noring U, Fog R et al. // Acta Psychiatr Scand. 1985. — V.71. — pp. 176−185.
- Preskorn SH. Outpatient Management of Depression. 2nd Ed. / Preskorn SH. // Caddo, OK, Professional Communications, Inc. 1999.
- Rochon PA. Atypical Antipsychotics and Parkinsonism. / Rochon PA, Stukel ТА. // Arch Intern Med. 2005. — V. 165(16). — pp. 1882−1888.
- Rodopoulos N. Assessment of dimethylxanthine formation from caffeine in healthy adults: comparison between plasma and saliva concentrations and urinary excretion of metabolites. / Rodopoulos N. // Scand J Clin Lab Invest. -1996.-V.56.-pp. 259−268.
- Rothstein MA. Pharmacogenomics Willy-liss. / Rothstein M.A. // New Jersey. 2003.
- Saruwatari J. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. / Saruwatari J. // Clin Pharmacol Ther. 2002. — V.72(2). — pp.200−208.
- Scandlyn MJ. Sex-specific differences in CYP450 isoforms in humans. / Scandlyn MJ, Stuart EC, Rosengren RJ. // Expert Opin Drug Metab Toxicol. 2008. — V.4(4). — pp. 413−424.
- Scott N. Caffeine clearance and biotransformation in patients with chronic liver disease. / Scott N et al. // Clin Sci (Lond). 1988. — V.74(4). — pp. 377−384.
- Setchell KDR. Rapid high-performance liquid chromatography assay for salivary and serum caffeine following an oral load. / Setchell KDR, Welsh MB. //J Chromatogr. — 1987. V.385. — pp. 267—274.
- Shah VP. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. / Shah VP, Midha KK et al. // J Pharm Sci. 1992. — V.81.-pp. 309−312.
- Shirley KL. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. / Shirley KL, Hon YY et al. // Neuropsychopharmacology. 2003. — V.28. — pp. 961−966.
- Shyu JK. Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. / Shyu JK, Wang YJ et al. // Zhonghua Yi Xue Za Zhi (Taipei). 1996. — V.57(5). — pp. 329−334.
- Simon. Drug therapy in the elderly: Improving quality and access. / Simon, Gurwitz. // Clin Pharmacol Ther. 2003. — V. 73.
- Simpson GM. Clozapine plasma levels and convulsions. / Simpson GM, Cooper ТА. // Am J Psychiatry. 1978. — V. 135. — pp. 99−100.
- Simpson GM. Double-blind study of clozapine dose response in chronic schizophrenia. / Simpson GM, Josiassen RC et al. // Am J Psychiatry. -1999.- V.156. -pp. 1744−1750.
- Sinues B. Five Caffeine Metabolite Ratios to Measure Tobacco-induced CYP1A2 Activity and Their Relationships with Urinary Mutagenicity and
- Urine Flow. / Sinues B, Saenz M. // Cancer Epidemiol Biomarkers. 1999. — V.8. — 159−166.
- Smith P. Report from the expert working group on the safety aspects of dietary caffeine. / Smith P, Smith A. 2005.
- Smith PF, Yi-Min Ku MS. Pharmacotherapy Self-Assesment th
- Programm 4 Edition. pp. 3−23. // www.accp.com/bookstore.php.
- Smith RC. Lower dose therapy with traditional neuroleptics and chronically hospitalized schizophrenic patients (letter). / Smith RC. // Arch Gen Psychiatry. — 1994. — 51.—pp. 427−429.
- Smith T. The effects of clozapine on plasma nortriptyline concentration. / Smith T, Riskin J. // Pharmacopsychiatr. 1994. — V.27. — pp. 4142.
- Sohler NL. American Psychiatric Association. Antipsychotic Dosage at Hospital Discharge and Outcomes Among Persons With Schizophrenia. / Sohler NL, Walkup J. // Psychiatr Serv. 2003. — V.54. — pp. 1258−1263.
- Spigset O. The paraxanthinexaffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the samples be obtained? / Spigset O. // Pharmacogenetics. 1999. — V.9. — pp. 409−412.
- Sweetman S. C. (ed.), Martindale. The Complete Drug Reference. The Pharmaceutical Press, London. — 2005.
- Tanaka E. Simultaneous determination of caffeine and its primary demethylated metabolites in human plasma by high-performance liquid chromatography. / Tanaka E. // J Chromatogr. —1992. V.575. — pp. 311—314.
- Tang В. Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. / Tang B, Grant D. // Drug Metab Dispos. 1983. — V. 11. — pp. 218−220.
- Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal fators on urinary phenotypic trait measurements. Pharmacogenetics. 1994−4:117−124.
- Tannergren C. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. / Tannergren C, Engman H, Knutson L et al. // Clin Pharmacol Ther. 2004. — V.75(4). — pp. 298 309.
- Tassaneeyakul W. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and ЗА isoforms. / Tassaneeyakul W, Birkett DJ et al. // Biochem Pharmacol. 1994. — V.18. — V.47(10). — pp. 1767−1776.
- Taylor D. Low dose typical antipsychotics a brief evaluation. / Taylor David // Psychiatric Bulletin. — 2000. — V.24. — pp. 465−468.
- Tse GH. Prolonged toxicity after massive olanzapine overdose: two cases with confirmatory laboratory data. / Tse GH, Warner MHJ. // Toxicol Sci. -2008. V.33(3). — pp. 363−366.
- Van Os J. Tardive dyskinesia: who is at risk? / Van Os J., Fahy Т., Jones P. E. // Acta Psychiatrica Scandinavica. — 1997. — V.96. — pp. 206−216.
- Van Putten Т. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. / Van Putten T, Marder S, Mintz J. // Arch Gen Psych. 1990. — V.47. — pp. 754−758.
- VanderZwaag C. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. / VanderZwaag C, McGee M, McEvoy JP et al. // Am J Psychiatry. 1996. — V. 153. — pp. 15 791 584.
- Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis. 1992−13:1561−1568.
- Volavka J. Plasma haloperidol levels and clinical effects in schizophrenia and schizo-affective disorder. / Volavka J, Cooper ТВ, Czobor P, Meisner M. // Arch Gen Psychiatry. — 1995. — V.52. — pp. 837−845.
- Wahllander A. High-performance liquid chromatographic determination of dimethylxanthine metabolites of caffeine in human plasma. / Wahllander A, Renner EJ. // Chromatogr. 1985. — V.338. — pp. 369−375.
- Wahllander AJ. Assesment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night. / Wahllander AJetal. // Hepatology.- 1990. V.10.-pp. 129−137.
- Walsky RL. Validated assays for human cytochrome P450 activities. / Walsky RL, Obach RS. // Drug Metab Dispos. 2004. — V.32. — pp. 647−660.
- Wang B. The Involvement Of CYP3A4 And CYP29 In The Metabolism Of 17n-Ethynylestradiol. / Wang B, Sanchez RI et al. // Drug Metab Dispos. 2004. — V.32. — pp. 1209−1212.
- Wang Z. Effect of St. John’s wort of the pharmacokinetics of fexofenadine. / Wang Z, Hamman MA, Huang SM et al. // Clin Pharmacol Ther. -2002. -V.71(6). -pp. 414−420.
- Weiden PJ. EPS profiles: The atypical antipsychotics are not all the same. / Weiden PJ. // J Psychiatr Pract. 2007. — V.13. — pp. 13−24.
- Yuan R. Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions. / Yuan R, Madani S et al. //DrugMetab Dispos. 2002. — V.30. — pp. 1311−1319.
- Zylber-Katz E. Relationship between caffeine concentrations in plasma and in saliva. / Zylber-Katz E et al. // Clin Pharmacol Ther. 1984. -V.36(l). — pp. 133−137.